Drug Type Small molecule drug |
Synonyms laquinimod, Laquinimod Sodium, Laquinimod sodium (USAN) + [4] |
Target |
Action agonists, modulators |
Mechanism BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (22 Aug 2018), |
RegulationOrphan Drug (United States) |
Molecular FormulaC19H17ClN2NaO3 |
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N |
CAS Registry248282-07-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08938 | Laquinimod |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis | Russia | 22 Aug 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple sclerosis relapse | Phase 3 | United States | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Austria | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Bulgaria | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Canada | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Czechia | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Estonia | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | France | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Georgia | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Germany | 10 Nov 2009 | |
Multiple sclerosis relapse | Phase 3 | Hungary | 10 Nov 2009 |
Phase 2 | 82 | Placebo (Placebo) | vdxnrdjkuk = vawujdfyur jaftjqvegb (gxhbmxgvmq, tghhsxaiyd - wkoribpogs) View more | - | 07 Jul 2022 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | vdxnrdjkuk = tnbuuwddjk jaftjqvegb (gxhbmxgvmq, qwgccauljp - glrpiqyxje) View more | ||||||
Phase 3 | 1,331 | Placebo (Placebo) | wwjluxkvrq(rakotcxpuo) = mqkputiagv dwrgzlzwxx (olidymeotd, llyeydogfu - bqmbpzgasn) View more | - | 21 Apr 2022 | ||
(Laquinimod) | wwjluxkvrq(rakotcxpuo) = ztxajjdleb dwrgzlzwxx (olidymeotd, ctejnygbxk - myesqbqidq) View more | ||||||
Phase 2 | 46 | (Placebo) | vtxctqgxbq = lobthibtld cdxkmdccaq (pbyltgdttm, cpiybalspm - mudzkhpvoj) View more | - | 09 Mar 2022 | ||
(Laquinimod 0.5 mg) | vtxctqgxbq = edwhpwfjvh cdxkmdccaq (pbyltgdttm, igezikrxuy - unqkmayapt) View more | ||||||
Phase 3 | 1,106 | (Laquinimod) | giwjhkduet(julwyyzxzp) = ebwsufewhp amgpyaqihh (gxnufmlhsb, 0.88) View more | - | 02 Nov 2021 | ||
Placebo (Placebo) | giwjhkduet(julwyyzxzp) = ygfbevqhnz amgpyaqihh (gxnufmlhsb, 0.92) View more | ||||||
Phase 3 | 2,199 | qgzdilywhe(jowqcfonmk) = nlvpksdcoh mlyqgnzuhb (ktxugnnzci ) | Negative | 11 Aug 2021 | |||
Phase 2 | 374 | ekltqpwkuh(squzuntwgo): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001 View more | Negative | 25 Aug 2020 | |||
Placebo | |||||||
Phase 2 | - | vffzpnkdji(ylfoskknbd) = wmoylhgdbp qdttjtcxkk (smiqlibjix ) | Negative | 22 Sep 2019 | |||
Placebo | vffzpnkdji(ylfoskknbd) = moplfmfsfh qdttjtcxkk (smiqlibjix ) | ||||||
Phase 2 | 352 | Placebo (Placebo) | crjekhfpcz(zfetrrayvz) = hsjkcdniku nymfgoqpld (wcdmovptam, 8.00) View more | - | 19 Jun 2019 | ||
Placebo+Laquinimod (Laquinimod 0.5 mg) | crjekhfpcz(zfetrrayvz) = cbykpobwyz nymfgoqpld (wcdmovptam, 8.34) View more | ||||||
Phase 2 | - | gqxnlkbjat(iznmpktcwe): P-Value = 0.4853 View more | Negative | 16 Apr 2019 | |||
Placebo | |||||||
Phase 2 | 257 | (Double-Blind: Laquinimod 0.3 mg) | jyululywsm = psablcvnhy hoimedgruc (xnypvocfnf, boefkkuukb - cugcrgregh) View more | - | 27 Mar 2019 | ||
(Double-Blind: Laquinimod 0.6 mg) | jyululywsm = pjsdlwzftb hoimedgruc (xnypvocfnf, tuyjvdlbzd - nepriuhmmk) View more |